Abstract
Disclosed herein are combined therapies for treating a hematologic malignancy (e.g., acute myeloid leukemia (AML), or myelodysplastic syndromes (MDS)), using an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17), and one or more chemotherapeutics, e.g., a Bcl2 inhibitor such as venetoclax, a hypomethylating agent (HMA), or a combination thereof.
Full Text
What is claimed is:
Disclosed herein are combined therapies for treating a hematologic malignancy (e.g., acute myeloid leukemia (AML), or myelodysplastic syndromes (MDS)), using an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17), and one or more chemotherapeutics, e.g., a Bcl2 inhibitor such as venetoclax, a hypomethylating agent (HMA), or a combination thereof.
Timeline
Filed
04/17/2026Published
08/06/2026Granted
Not AvailableIPC Codes(6)
C07K 16/28:against receptors, cell surface antigens or cell surface determinants
A61K 9/00:Medicinal preparations characterised by special physical form
A61K 31/496:Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin